Sanofi (SNY)
| Market Cap | 107.16B -14.3% |
| Revenue (ttm) | 55.89B +7.0% |
| Net Income | 4.52B -56.6% |
| EPS | 1.86 -55.6% |
| Shares Out | 1.20B |
| PE Ratio | 23.70 |
| Forward PE | 8.57 |
| Dividend | $1.76 (3.97%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 2,170,243 |
| Open | 44.68 |
| Previous Close | 44.37 |
| Day's Range | 44.43 - 45.22 |
| 52-Week Range | 40.89 - 52.68 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 53.72 (+20.8%) |
| Earnings Date | Jul 30, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $53.72, which is an increase of 20.80% from the latest price.
News
Novavax's XFG-Adapted Nuvaxovid Approved In U.S., EU, Japan For 2026-2027 Season
(RTTNews) - Novavax, Inc. (NVAX) on Friday announced that its partners, Sanofi and Takeda, have received regulatory approvals for XFG-adapted Nuvaxovid COVID-19 vaccine for the 2026-2027 vaccination s...
US FDA approves updated COVID vaccines for 2026-27 season
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shot...
Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?
The FDA just approved the company's on-body injector for its blood cancer drug. Analysts see upside potential ahead for shares of the French pharmaceutical giant.
Sanofi price target lowered to EUR 82 from EUR 86 at Morgan Stanley
Morgan Stanley analyst Sarita Kapila lowered the firm’s price target on Sanofi (SNY) to EUR 82 from EUR 86 and keeps an Equal Weight rating on the shares. Published first…
Sanofi facing shortages of two drugs for Pompe disease, STAT reports
Sanofi (SNY) is facing shortages of Myozyme and Nexviazyme for Pompe disease after manufacturing and quality-control issues at its Waterford facility, which was cited by the FDA in June for…
Novavax Q2 Earnings Call Highlights
Analysts Think These Stocks Could More Than Double in ValueNovavax (NASDAQ:NVAX) reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in its S...
Sanofi's MenQuadfi Wins EC Approval For Use In Six Week Old Infants Against Meningococcal Disease
(RTTNews) - Sanofi (SNY) announced on Tuesday that the European Commission (EC) has approved an expanded indication for MenQuadfi for use in infants from six weeks of age to help protect against invas...
Sanofi: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) ha...
Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has a...
Sanofi SA (SNY) Stock Down 4.5% -- Now Undervalued? GF Score: 70/100
Sanofi SA (SNY) Stock Down 4.5% -- Now Undervalued? GF Score: 70/100
Sanofi (SNY) Faces Stock Decline Amid CEO's Warning on Drug Pipeline Challenges
Sanofi (SNY) Faces Stock Decline Amid CEO's Warning on Drug Pipeline Challenges
Sanofi: Sanofi's half-year financial report for 2026
Sanofi's half-year financial report for 2026 Paris, July 30, 2026. Sanofi announces that its half-year financial report for the period ending June 30, 2026, is now available online and has been fi...
Sanofi Q2 Earnings Call Highlights
Sanofi NASDAQ: SNY raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also ...
Sanofi Q2 Earnings Call Highlights
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%Sanofi (NASDAQ:SNY) raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recentl...
Sanofi Earnings Call Transcript: Q2 2026
Q2 2026 saw double-digit sales and EPS growth, driven by strong pharma launches and Dupixent. Upgraded 2026 guidance reflects robust H1 results, with raised 2030 ambitions for Dupixent, pharma launches, and vaccines. Strategic R&D and portfolio reviews are underway to enhance long-term growth.
Sanofi Earnings release: Q2 2026
Sanofi released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Sanofi Slides: Q2 2026
Sanofi has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Sanofi Earnings release: Q2 2026
Sanofi released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Sanofi Quarterly report: Q2 2026
Sanofi has published its Q2 2026 quarterly earnings report on July 30, 2026.
Sanofi expects FY26 sales to grow by around 10% at CER
In 2026, sales are now expected to grow by around 10% at CER. Business EPS at CER is expected to grow slightly faster than sales.
Sanofi reports Q2 business EPS EUR 2.09, up 31.4% reported
Business EPS was EUR 2.09, up by 33.3% at CER; 31.4% at actual exchange rates; IFRS EPS EUR 0.29. Reports net sales EUR 11.6B, up 16% reported and 17.8% at…
Sanofi Q2 Net Profit Plunges, Business Profit Climbs On Strong Sales; Lifts FY26 Outlook
(RTTNews) - French drug major Sanofi SA (SNY, SNYNF, SAN.PA) reported Thursday sharply lower net profit in its second quarter, while business earnings climbed from last year with strong sales growth. ...
Sanofi Raises Guidance as New CEO Looks to Revamp Drug Pipeline
The company now expects 2026 sales to grow by around 10% excluding currency changes, with business earnings per share rising slightly faster than sales.
Sanofi raises sales outlook on Dupixent strength in boost for new CEO
Sanofi on Thursday raised its full-year sales forecast on the back of strong demand for blockbuster asthma drug Dupixent, with investors focused on new CEO Belen Garijo's first address for her plans...
Sanofi: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded July 30, 2026 Q2 sales growth of 17.8% at CER1 and business earnings per share (EPS)2 of €2.09 Pharma launc...